Case Study

DH20931 Discovery

The Problem

Due to lack of well-defined molecular targets, there are very few therapeutic options available for triple negative breast cancer (TNBC), which disproportionately affects young women and African American women as well as those with the BRCA1 gene. Given the suboptimal treatment outcome with current chemotherapy, the Breast Cancer Research Foundation said a solution to treat TNBC is “an urgent priority.”

Approximately 2.26M people are diagnosed with invasive breast cancers annually. Approximately 20% of them are TNBC. TNBC has the worst prognosis and lowest-5 year survival rate compared to all other breast cancer subtypes.

The Solution

A novel small molecule, biisoquinoline-derivative DH20931.

DH20931

DH20931 is a first small molecule that activates CerS2 at nanomolar concentrations. Independent research demonstrates that DH2093 inhibits the growth of TNBC cells in vitro and in vivo with no toxicity. This patented drug candidate shows great promise in improving the treatment of breast and other cancers. The Investigational New Drug (IND) process by a world-class independent lab validates DH20931 significantly reduces the TNBC solid tumors with no toxicity.

U.S. Precision Medicine holds the exclusive option agreement for this molecule as well as other patented small molecule drugs—all based on the same science—to treat colorectal, prostate, uterine and ovarian cancers.